Compare Citius Pharmaceuticals Inc (CTXR) vs iShares 7-10 Year Treasury Bond ETF (IEF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs iShares 7-10 Year Treasury Bond ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while iShares 7-10 Year Treasury Bond ETF trades at $89.39 (market cap $41.13B). The key difference: iShares 7-10 Year Treasury Bond ETF is far larger — about 3019.8× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 10,340,382). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and iShares 7-10 Year Treasury Bond ETF for 108 Days on average.
| CTXR | IEF | |
|---|---|---|
Market Cap | $13.62M | $41.13B |
Volume | 132,438 | 10,340,382 |
Sector | Health | Fixed Income |
52-Week High | $1.82 | $97.99 |
52-Week Low | $0.48 | $88.92 |
Typical Hold Time | 17 Days | 108 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
IEF trades at $89.335, up 0.25% with a bearish technical signal from moving averages. The fund shows neutral oscillator readings with RSI at 52.94. Recent dividend payments of $0.31-$0.33 provide income, while bond market volatility and rising Treasury yields create headwinds. Support is clustered around $89 with resistance at $90.
The outlook remains cautious amid persistent bond market pressure. While dividend income offers stability, the bearish technical trend and macroeconomic uncertainty suggest limited near-term upside. Key risks include continued yield increases and inflation concerns that could pressure bond prices further.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →
